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Purely serological studies by means of complement-dependent cytotoxicity reactionsagainst
either chronic lymphatic leukemia cells (1) or B lymphocytes isolated from normal peripheral
blood (2), has led to the identification of distinct human B-cell-specific alloantigens. Extensive
population and family analysis through the cooperation program of the VII International
Histocompatibility Workshop has defined eight individual specificities (3). These behave as
products of alleles at a single locus and are also strongly correlated with the specificities of the
HLA-D locus. Thus those allospecificiiies are designed as HLA-DR (HLA-D related) specific-
ities.
However, many oftheanti-B-cell antisera studied in the VIIWorkshop couldnot be included
in the clusters corresponding to the eight defined DR specificities and some of them may
recognize distinct non-DR specificities, as well as other still unidentified DR allelic products.
Data obtained in the mouse system also show that la antigens which are specific to B
lymphocytes are associated with at least three distinct I subregions (4) and different structural
genes should code for the subunit(s) controlled by the H-2 region.
Independently from these serological studies, cell membrane glycoproteins which are ex-
pressedon B lymphocytes have recently been purified andcharacterized (5-7). They consist of
two noncovalently linked polypeptide chains, i.e. a largesubunit of32,000-35,000 daltons and
asmall subunit of 25,000-28,000 daltons. They are not present on Tlymphocytes. In this sense
they are classified as B-cell-specific antigens and may well be the human equivalent of mouse
la antigens.' At least two loci, corresponding to the two basic subunits are involved in the
synthesis of human Ia-like antigens. One of the two subunits is reportedly controlled by an
HLA-unlinked locus (8).
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' Note on nomenclature: three termsare currentlyused,differing in theiroperational meaning, to define
thesame or relatedentities: (a) la-like antigens or molecules, (b) B-cell-specific antigens, and (c) HLA-DR
antigens. We refer to Ia-like antigens as molecules possessing similar structures and tissue distribution as
murine Ia antigens. The term B-cell-specific antigens will be used to generally indicate antigenicspecificity
present on B but not on T lymphocytes, irrespective of their representation on other cells. HLA-DR
antigens (D locusrelatedantigens) is amuch more specific term indicating these alloantigenic determinants
recognized by the clusters of antisera sorted out by the analysis of the data obtained during the VII
Histocompatibility Workshop (3) and possessing a very high correlation with HLA-D locus specificities as
defined by mixed lymphocyte culture reactions. Terms (a) and (b) will become equivalent only if all the
alloantigenic specificities found on B but not on T lymphocytes will be shown to reside on the same
molecularspecies and to have the same tissue distribution. Terms (b) and (c) can become synonyms only
if the hypothesis of asingle HLA-linked locusspecifying all B-cell alloantigenic structures is true.
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In the present work a fusion of the biochemical and immunogenetical approaches
is attempted, with the aims of: (a) obtaining direct evidence of the association of a
defined DR specificity as determined by cytotoxicity reactions with a specific molec-
ular entity, and (b) testing whether the la molecule pool can be dissected by means of
specifically reacting alloantisera into distinct subsets corresponding to different gene
products.
The test system adopted has been the classical B-cell type cell line, Daudi, which
has been used for studies of la-like antigens because it does not express HLA (A,B,C)
molecules.
Materials and Methods
Cultured Cells.
￿
Cells of a human B-cell type cell line, Daudi, were cultivated in spinner
culture or stationary bottle culture with RPMI-1640 medium supplemented with 10% heat-
inactivated fetal bovine serum. The cells for cytotoxicity tests were harvested at culture day 2
and used immediately. The cells used for isolation of human Ia molecules were harvested at
culture day 2 or 3, washed with phosphate-buffered saline, packed at 600 g for 10 min and kept
frozen at -70°C until used.
The Daudi cells we used did not carry any HLA (A,B,C) allospecificity and did not produce
P2-microglobulin in accord with reports by others (9-11). Although, Ostberg et al. (12) have
reported that the Daudi cells they used did contain HLA (A,B,C) antigens that can be detected
by rabbit antiserum against HLA (A,B,C) antigens, we could not find such substances (7) .
Preparations of 125
1-Labeled Human Ia Molecules.
￿
Human Ia antigens partially purified from
Renex 30 (Ruger Chemical Co., Irvington, N. J.)- solubilized membrane materials of Daudi
cells by the method described previously (7) were radioiodinated and further purified by a
series of procedures that involved enzymatic cleavage with papain (13).
Crude cell membranes were isolated by differential centrifugation from 10 g of Daudi cells
(=5 X 109 cells) disrupted by nitrogen decompression (800 pound per square inch) (14). The
crude membranes (wet weight 1 .3 g) were homogenized with four parts of 2% Renex 30 in Tris-
HCl buffer (iris 0.075 M, pH 7.8). After standing for 30 min at room temperature, the
homogenate was centrifuged at 105,000 g for 60 min and the supernate was harvested. This
solubilization process was repeated twice and the supernates were combined. The yield in A280
units was 172.
The Renex 30-solubilized membrane materials were then subjected to affinity chromatog-
raphy on a Lens culinaris hemagglutinin (LcH)-coupled Sepharose column (LcH 4 mg/ml gel,
bed vol 5 ml). The retarded fraction was eluted with a 2% mannoside solution. The recovery of
A28o units in the retarded fraction was 4.8. The major portion of the retarded fraction was then
fractionated by gel filtration on a Bio-Gel A1.5 M column (bed vol 100 ml) . The human la
activity, as assayed by the radioimmune inhibition assay (7), was found in fractions correspond-
ing to about 200,000 daltons. The major fractions were pooled. The yield in A28o units was 0.41 .
A small amount (0.014 A28o units) ofthe pool was labeled with radioactive iodine-125I by the
chloramine-T method to give a specific radioactivity of about 20 mCi/A28o unit (15) . The
radiolabeled preparation was digested with papain in the presence of a carrier protein at 37 °C
for 30 min. The ratio of enzyme to substrate (1.0 ml of a 7.34 A280 units/ml carrier protein
solution) was 1:40. The carrier protein used was the LcH unretarded fraction of Renex 30-
solubilized membrane materials of Daudi cells. It was used after exposure to pH 2.3 for 30 min.
This carrier did not contain any human Ia antigens, because la molecules are mostly removed
on LcH affinity chromatography and are labile at acid pH (7).
Papain digestion split a substantial proportion of contaminants and also some of the Ia
molecules leaving the remaining intact and thus increasing the purity of the preparation (13) .
After gel filtration of a Bio-Gel A1 .5 M column (bed vol 50 ml), the separated modified Ia
molecules (i.e. papain-split fractions) were further purified by LcH affinity chromatography as
described previously (7).
Antisera.
￿
Heteroantisera used were the following: rabbit anti-#2-microglobulin antiserum
raised against a purified preparation of human,82-microglobulin (16), rabbit anti-HLA (A,B,C)
antiserum raised against a purified preparation ofpapain-solubilized HLA antigens (17), rabbit1594
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TABLE I
Synopsis ofRelevant Antisera
* This is indicated for those antisera which were studied during the VII International Histocompatibility
Workshop. More information on these sera can be obtained in the Workshop report (Histocompatibility
testing 1977, in press).
$Specificity either derived from the Workshop results or indicated by the laboratory of origin from the
serological reactions in a local typed panel.
§This column indicates the specificities that can be detected in these antisera when reacted with a purified
Daudi Ia preparation. Each antiserum mayobviously possess additional specificities.
anti-Fab fragments of normal human IgG, rabbit anti-B-cell membrane antiserum produced
by immunization with crude membrane materials of a B-cell type cell line, RPMI-8235 (7),
rabbit anti-B-cell glycoprotein antiserum raised against a crude preparation of membrane
glycoproteins with LcH affinity obtained from a B-cell type cell line, B46M (7). In addition,
rabbit anti-P23.30 antiserum that is specific to B-cell-specific antigens (5) was used. This was
kindly provided to us by Dr. R. E. Humphreys, University of Massachusetts Medical School,
Worcester, Mass.
Most of the alloantisera used in this work was obtained by planned immunization ofblood
donor volunteers selected according to their HLA phenotype. Details on this extensive immu-
nization program have been previously reported (18, 19) . Other reagents have been obtained
by serum exchanges with other laboratories or from the NIH serum bank. All antisera were
used without prior absorption with platelets. The antisera listed in Table I, after apreliminary
screeningoftheir cytotoxic andIa binding activity, were selected for theimmunological analysis
of Daudi Ia molecules.
Direct Binding Test.
￿
Assay conditions have been previously described in detail (20) . For the
screening of the binding activity of antisera, equal portions of an t ￿-labeled Ia preparation of
Antiserum Laboratory of origin 7W. num-
ber* Nominal specifcity$
Specificity de-
tected on Daudi
Ia§
TH 21 .3.75 Thorsby DRw3 + 6 DRw6
TH 19 Varen 75 Thorsby DRw3 + 6 DRw6
FD 8013 P1 Engelfriet Unknown DRw6
406 Stasmy 7W111 DRw3 + 6 DRw6 + weak
DC-1
CLB 811.1 Engelfriet 7WO46 DRw2 + 6 DRw6 + DC-1
19941/76 Kissmeyer 7WO66 DRw2 + DRwl DC-1
Fordice 28.1 .70 Yunis Unknown DC-1
Cerny 7.12.72 Yunis Unknown DC-1
CLB 833.2 Engelfriet 7WO07 Unknown DC-1
Corazzola 418 Jeannet DRw2 + DRw3 DC-1
Rettler9.9.70 Yunis 7W150 Unknown DC-1
Fe 131/4, /6 Ferrara Unknown DC-1
Fe 77/43 Ferrara Unknown DC-1
Fe 96/11 Ferrara Unknown DC-1
Fe 67/15 Ferrara Unknown DRw6 + DC-2
+ x
Fe 88/37 Ferrara Unknown DRw6 + DC-2
+ x
Fe 75/39 Ferrara Unknown DRw6 + DC-2
+ x
Molimer567 Jeannet DRw5 DRw6 + DC-1
+ x
Betz Tanigaki Unknown DRw6 + x
TO-29-01 Ceppellini (NIH bank) Unknown BroadTOSI, TANIGAKI, CENTIS, FERRARA, AND PRESSMAN
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about 20,000 cpm were incubated with 10 111 of undiluted antiserum in the presence of 0.2%
Renex 30 and0.02% bovine serum albumin (BSA).2 After incubation for 16 h at 37°C, 70111 of
goat anti-human IgG serum was added. After further incubation for 30 min at room temper-
ature, the immune precipitate was washed and the radioactivity was determined. A control
with normal serum (in duplicate) was included in each experiment. Test with rabbit antisera
was the same, except that 4111 of antiserum, either undilutedor diluted in normal rabbit serum,
were used, and 20 ul of goat anti-rabbit IgG was added as precipitating immune complex.
Results obtained with alloantisera in different experiments were referred to the proportion of
radioactivity bound by rabbit anti-B-cell membrane antiserum, by the following expression:
% Ia binding
￿
cpm boundby alloantiserum - cpm bound by normal human serum = - ￿X 100
cpm bound rabbit anti-B cell membrane antiserum - cpm bound
by normal rabbit serum
Sequential Binding Test. In experiments made either to determine the maximal proportion of
Ia moleculeswhichcouldbe bound by a given antiserum or made to determine therelationship
between the Ia molecules bound by the different antisera (cross-absorption experiments) the
following procedure was used: the first bindingstep was carried out on 250,000 cpm of antigen
with 50111 of antiserum for 2 h at 37°C. After addition of 350111 ofgoat anti-human IgG serum
and further incubation at 37°C for 30 min, the precipitate was washed and assayed for
radioactivity. The percentage of radioactivity bound was calculated with reference to the
radioactivity bound by rabbit anti-B-cell membrane antiserum on the starting material.
The supernate recovered after the first absorption was combined with a second 50-111 portion
of the same antiserum and incubated overnight at room temperature (second bindingstep). No
precipitate formed, a result in agreement with our previous determination that no goat anti-
human IgG antibody remained in the supernate. Afteranother addition of 35011l of goat anti-
human IgG serum and further incubation (30 min, 37 °C), the precipitate was washed and
counted and the percentage of radioactivity bound calculated relative to the radioactivity
bound by the rabbit anti-B-cell membrane antiserum on a portion of the supernate recovered
after the first binding step. This percent of binding was expressed as fractional binding of the
starting preparation; e.g., if the first binding was 19.4% of the total present and the second
binding was 7.1% of the total present at that time, then the latter, relative to the starting
preparation, is 0.71 X (100 - 19.4) = 5.7%, and thecumulative binding after two steps is 19.4
+ 5.7 = 25.1 . In cross-absorption experiments, portions of the supernate after the second
binding step were allowed to react with different antisera under the same conditions.
Cytotoxicity Test.
￿
Theethidium bromidemethod (21) wasused. Dueto thepeculiar sensitivity
of cultured lymphoblastoid cells, the following precautions were adopted: (a) Daudi cells were
harvested during early exponential growth, (b) complement was selected for its minimal
cytotoxiceffect with controlsera coupled with a cleareffect using antisera of different strength,
(c) incubation times were shortened, as compared with those used for cytotoxicity test with
normal peripheral blood lymphocytes, to decrease the background killing in the presence of
complement.
The test was performed by adding 1 111 of cell suspension (1,000 cells) to 1 111 of undiluted
antisera. After a 30-min incubation at room temperature, 1 111 of complement (undiluted rabbit
serum) was added. Aftera further 30 min incubation, 1 ,ul ofa 0.01% ethidium bromidesolution
was added and the dead cellswere determined by theirfluorescence. Live cellswere determined
as thedifference between this number of dead cells and the total number of live and dead cells
as determined under normal light. Percentages of dead cells were assigned on the basis of two
independent readings. Scores were then assigned in the following way: score 1: 0-30%v killing,
2: 30-50%, 3: 50-70%, and 4: 70-100%. The background killing controls (complement plus so
called normal serum) could not be completely eliminated and amounted to 10-30%. Only
scores 3 and 4 were thus considered as significant.
Separation of the Large and Small Subunits ofHuman Ia Molecules.
￿
1251-Daudi la preparation was
'Abbreviations used in this paper: BSA, bovine serum albumin; L/S, large subunit/small subunit ratio;
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TABLE II
Binding Characteristics ofan '251-Labeled Daudi Ia Preparation
Antiserum Percent of radioactivity
bound*
Equal portions of an 125I-labeled Daudi la preparation of about 20,000 cpm
were incubated with 4 g.I of each rabbit antiserum for 1 h at 37°C. The
immune complex was precipitated by an excess of goat anti-rabbit IgG
antiserum. Theradioactivity in theprecipitate wasdetermined andexpressed
as the percent of the total added radioactivity. The amount of rabbit anti-
HLA, anti-N2-microglobulin and anti-Fab fragment antisera was large
enough to obtain the maximum level of binding in the reaction with the
corresponding antigen preparation. In the case of TO-29-01 and its control,
the data obtained by three-step cumulative binding test (Materials and
Methods) are given.
prepared as described above except that it was not subjected to papain digestion. 400 ltl (9 X
106 cpm) of the labeled preparation was incubated with 50 ltl of a 10% sodium dodecyl sulfate
(SDS) solution (noreducing agent was used) for 30 min at 56 °C. The mixture was subjected to
electrophoresis on a 12% gel (10 X 90 mm) containing 0.1% SDS (22) . The gel was segmented
at a 2 mm setting by an automatic gel divider (Gilson Medical Electronics, Inc., Middleton,
Wis.) . The separated portions were eluted by incubating each with a 0.5 ml of Tris-HCI buffer
(Tris 0.075 M, pH 7.8) containing 0.2% Renex 30 and 0.02% BSA overnight at 4°C.
Results
The Purified Daudi la Preparation.
￿
Table II shows the binding properties of the
radiolabeled la preparation which was utilized for the subsequent immunological
analysis. The purity amounts to about 70%, as determined by two different rabbit
anti-la antisera which could specifically recognize B-cell antigens in this preparation.
Anti-P 23.30 antiserum gave approximately the same binding, indicating analogy
with the Ia-like substance isolated by Humphreys et al. (5).
No significant binding was observed with antisera directed against other defined
surface markers.
A broadly reacting alloantiserum, TO-29-01, obtained from the NIH serum bank
gave a binding similar (after subtraction of control binding) to that shown by rabbit
anti-B-cell antisera. After three sequential steps, over 90% of the la molecules were
bound by this antiserum, showingthat most, ifnot all, la molecules carry alloantigenic
determinants.
Analysis of the immunoprecipitates obtained with the different antisera by SDS-
polyacrylamide gel electrophoresis showed a typical la pattern, with two spikes
corresponding to a large (32,000 daltons) and a small (25,000 daltons) subunit of
human la molecules (Fig. 1) as previously reported (7, 13).
Rabbit anti-B-cell membrane (no. 5329) 72.2
Rabbit anti-B-cell glycoprotein (no. 7150) 65.4
Rabbit anti-P23-30 65.8
Rabbit anti-HLA (A, B, C) 0.9
Rabbit anti-#2-microglobulin 1 .0
Rabbit anti-Fab fragment 1 .7
Normal rabbit serum 1 .2
Alloantiserum TO-29-01 73.3
Normal human serum 6.9TOSI, TANIGAKI, CENTIS, FERRARA, AND PRESSMAN
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FIG. 1.
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Analysis by SDS-polyacrylamide gel electrophoresis of Daudi la molecules bound to (a)
rabbit anti-B-cell membrane antiserum andto (b) alloantiserum TO-29-01. Asmall amount (:20,000
cpm) of '251-labeled Daudi la preparation was allowed to react with 4 111 of rabbit anti-B-cell
membrane antiserum or with 10 tal of TO-29-01. The soluble immune complex wasprecipitated with
an excess of goat anti-rabbit IgG or goat anti-human IgG antiserum. The precipitate containing
14,000 cpm for rabbit anti-B-cell membrane and 10,000 cpm for TO-29-01 was treated with 50 WI of
a5% SDS solution (without reducing reagent) andsubjected to electrophoresis on a 12% polyacryl-
amide gel (6 X 90 mm) containing 0.1% SDS (23). The gel was sliced into 40 segments from the
cathode end by an automatic gel divider andeach segment was assayed for radioactivity.
The figures are plots of radioactivity against segment number. Thecurves are arranged to show
that the patterns are essentially identical to each other with respect to number and position of the
1251-radioactivity peaks. Thetwo major radioactivity peaks correspond to 32,000-dalton and 25,000-
dalton subunits of Ia molecules as reported previously (7) . The 1251-radioactivity peak preceding
them may be an impurity in case of rabbit anti-B-cell membrane antiserum. In case of TO-29-01, it
maybe dueto undissociated la molecules. In both cases, the last 125I-radioactivity peak is apparently
due to a la fragment(s), because the control precipitate prepared with a normal rabbit serum or
with anormal humanserum did not give such a radioactivity peak (not shown) .
Relationship between Complement-Dependent Cytotoxic Activity against Daudi Cells and
Binding of Purified Daudi la Molecules by Alloantisera. A screening of 270 antisera from
different laboratories was performed both by cytotoxicity assay and by direct binding
assay. A general agreement was found between the two sets ofdata, as shown in Table
III. Only three instances of positive cytotoxicity reactions were seen which were not
coupled to significant la binding activity. On the other hand, at least seven antisera
which were shown on repeated tests to be devoid of cytotoxic effect gave a significant
la binding. The most evident example was serum Molimer which binds 77 .8% of Ia
molecules although being completely inactive in the cytotoxicity test.
All anti-DRw6 antisera tested gave strongly positive reactions on both tests. No
positive results were given by the groups of antisera defining the other DR specificities.
This agrees with the analysis performed on Daudi cells by different laboratories
during the VII Histocompatibility Workshop (3), indicating that DRw6 is the only
recognized DR specificity present on Daudi cells. Several antisera possessing anti-DC-
1 activity (see below) gave either weak or negative cytotoxic reactions on repeated
tests (Table III) .
ImmunologicalAnalysis ofDaudi la Molecules.
￿
The antisera which on the preliminary
screening were found to possess significant binding activity were further studied to1598
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TABLE III
Comparison between Cytotoxicity Data and Ia Binding Data*
* The antisera which possess anti-DC-1 specificity are indicated in parentheses.
define as closely as possible (with the limitations due to the generally low avidity of
alloantisera) the proportion of Ia molecules that could be maximally bound. To this
aim, each antiserum was titrated to find whether a plateau level of the maximum
amount of la molecules bound could be obtained. Also, each antiserum was tested in
sequential binding experiments with three subsequent additions of equal portions of
antiserum. A cumulative binding proportion, as referred to the starting material, was
thus determined.
A qualitative comparison between the la molecules bound by the different antisera
was then made by reciprocal absorption experiments, i.e. by removing the molecules
reacting with one antiserum and testing the remaining material with the other
antisera.
Information on the proportion of molecules that each antiserum maximally binds
was then combined with information on the specificity of each antiserum derived
from the absorption data. A comprehensive picture of the alloantigenic heterogeneity
of Daudi la molecules was thus obtained (Fig. 2). Three components (DRw6, DC-1,
and DC-2) were defined with sufficient precision on the basis of different antisera
sharing the same reactivity pattern. A portion of la molecules corresponding to about
25-30% of the total (shaded area, Fig. 2), remains undefined. Their immunological
analysis must await the availability ofotherspecific antisera. These molecules however
do carry alloantigenic determinant, as shown by their reactivity with.antiserum TO-
29-01 (Table II), antiserum Fe 75/29 (Fig. 2), and antiserum Betz (Fig. 2) .
SPECIFICITY DRW6. Because DRw6 was the only defined DR specificity detected on
Daudi cells in the VII Workshop serological analysis, this was a logical starting point .
Three antisera were available to us with nominal DRw6 specificity: two were
Thorsby's antisera (TH 21 .3.75 and TH 19 Varen 75) and one was from Stastny
(antiserum 406, corresponding to VII Workshop antiserum 111) . In addition, an
antiserum from Engelfriet, FD 8013P1 was found very similar to the Thorsby's
antisera and was classified as an anti-DRw6. All four antisera were strongly cytotoxic
against Daudi cells. When titrated, it was apparent (Fig. 3) that none of the antisera
reached a binding plateau at the maximum amount used (10 pl). A somewhat higher
proportion of molecules could be bound by each antiserum by three sequential
antiserum additions (Fig. 4). Antiserum 406 reacted weakly against an additional
component (see below) ; the other three antisera, which were considered as represent-
ative of the DRw6 specificity gave an average cumulative binding of 30.2% (27.0,
29.2, 34.5) .
la binding
(% of radioactivity bound)
>10 5-10 <5
Cytotoxicity (% of cells killed)
>70 23 (8) 0 1
50-70 7 (3) 2 2
0-50 7 (4) 8 220TOSI, TANIGAKI, CENTIS, FERRARA, AND PRESSMAN
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Immunological analysis of Daudi la molecules. Each antiserum is represented by a column
of a length corresponding to the percentage of la molecules it can maximally bind, as determined
by a three-step sequential binding assay (Materials and Methods). The position of each column
reflects the results of cross-absorption experiments. The arrangement of the whole set of antisera is
internally consistent. On the left hand side the designation of the identified subsets as well as their
approximate contribution to the Daudi la pool is indicated.
III
￿
I III
Sequemnl Dvdeq steps
FIG. 3.
￿
Titration of anti-DRw6 antisera. Plots of percent of Daudi la preparation bound against
volume of various antiserum added. Equal portions of I251-labeled Daudi la preparation containing
about 20,000 cpm were incubated (24 h at 37 OC) with different amounts of antiserum, either
undiluted or diluted in normal human serum. Percentages of la binding were calculated after
subtraction of the counts bound by 10 ji1 of normal serum and divided by the counts bound by
rabbit anti-B-cell membrane antiserum, as indicated under Materials and Methods. Note that only
antisera TH 21 .3.75 and TH 19 Varen 75 appear to approach aplateau value at the largest amount
of antiserum used.
THZ1 .a75
F08013 3 -PI
THiewmre
FIG. 4.
￿
Proportion ofDaudi la molecules cumulatively bound by four anti-DRw6 antisera used in
sequence. Each column represents the percentage of Ia molecules bound at a given step plus the
preceding step(s), calculated as described under Materials and Methods. Broken horizontal lines
indicate the maximum binding observed in the direct titration of each antiserum, as shown in Fig.
3.
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A further attempt to determine the total amount of DRw6-positive molecules was
made by 10-fold increasing the antibody-antigen ratio as compared with the highest
point in Fig. 3, i.e. by using 20 gl of antiserum instead of 10 and 4,000 cpm of antigen
instead of 20,000. Although under these rather extreme conditions unspecific binding
may influence the results, the following binding percentages were obtained, TH
21.3.75 : 39.8%, TH 19 Varen 75: 39.0%; FD 8013 P1 : 34.5%. It can be concluded
that, with the limitation due to the low avidity of these antisera, a maximum of 40%
of the Daudi Ia molecules, (but, more likely, a proportion lying between 30 and
35%) do carry the DRw6 determinant.
To establish whether the molecules bound by the three antisera were the same,
reciprocal absorption experiments were performed. This kind of experiment is com-
plicated if the maximum binding (plateau achieved) is not obtained in the determi-
nation with the first antiserum. Even though two antisera may be reacting identically,
absorption with one of them is only expected to reduce, not to eliminate the binding
by the other. Table IV shows that absorption (two sequential steps) by any of the
three antisera produced a strong reduction, as compared to controls, of binding by
the other two. Additional proof that the three antisera recognize the same molecules
is that their binding is reduced in a parallel fashion by absorption with other more
complex antisera: CLB 811 .1, Molimer, Betz, Fe 88/37, Fe 67/15, Fe 75/39 (data not
shown).
SPECIFICITY DC-1. A group of 15 antisera was found in the preliminary screening
possessing a similar binding capacity ( 15-20% binding) . Out of these antisera four
were chosen for more detailed study; of these two (19941/76 and Fordice) showed on
titration a definite plateau of binding, while the others (Fe 96/11 and Fe 77/43)
closely approached a plateau (data not shown) . Data in Table V show that this is a
homogeneous group of antisera, recognizing an alloantigenic determinant on Daudi
la molecules. This new specificity was called DC-1 . From the cumulative percent of
binding obtained by the four antisera, the proportion of molecules carrying DC-1 can
be estimated as 24.8% (average of 25.8, 24.8, 25.8, 22.8) . Cross-absorption experiments
show that DC-1 and DRw6 are carried by different molecules since absorption with
antisera belonging to one group does not significantly reduce, in any of the combi-
nations tested, the binding ofantisera belonging to the other group. Most of the time,
such absorption induced an enrichment of the molecules carrying the other determi-
nant and thus an apparent increase of binding (Table VI) .
Anti-DC-1 antibodieswere detected in two otherantisera, Molimer and CLB 811 .1,
by cross-absorption. Both antisera also contain anti-DRw6 antibodies (data not
shown) . Although Molimer is a broadly reacting antisera (77.8% of three-steps
cumulative binding), CLB 811.1 appears to be a duo-specific antiserum ofDRw6 and
DC-1 specificities because its cumulative binding (51 .6%) fits the sum of DC-1 and
DRw6-positive molecules (Fig. 2) . Antiserum 406 also contains anti-DC-1 antibodies
which can explain its higher binding, as compared with the other three anti-DRw6
sera (Fig. 3) . Anti-DC-1 specificity was also found in some antisera studied in the VII
Histocompatibility Workshop. For such antisera extensive serological data are avail-
able, because they have been tested with approximately 14,000 unrelated individuals.
As shown in Table VII, all the antisera possess a highly significant correlation with
DRw6 specificity.
SPECIFICITY DC-2. An additional determinant was identified on the basis of cross-TOSI, TANIGAKI, CENTIS, FERRARA, AND PRESSMAN
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TABLE IV
Absorption Patterns by Anti-DRw6 Antisera*
Note that absorption by any of the three antisera produced a strong reduction, as
comFared to controls, of binding by the other two.
* An 261-labeled Daudi la preparation of about 250,000 cpm was absorbed twice
sequentially with 50 ttl of a given antiserum. Equal portions of the supernate after
the second absorption were allowed to react with the absorbing antiserum and with
different antisera under the same conditions. The radioactivity bound was expressed
as the percent of the total radioactivity added at the time. The control binding
values (bottom of table) are those obtained with the labeled preparation absorbed
twice, under the same conditions with normal human serum (Materials and
Methods).
$ The percentages of la molecules bound to the absorbing antiserum (two sequential
absorption steps) are shown in parentheses.
§ This was calculated by dividing the experimental binding value (the preceding
column) by the control binding value obtained with the labeled preparation
absorbed with normal human serum.
absorption experiments, as a common specificity shared by three Ferrara's antisera:
88/37, 75/39, 67/15. None of these antisera is monospecific.3 All three contained anti-
DRw6 antibody but did not contain anti-DC-1 antibody. They reacted with 73.1%
(Fe 75/39), 65.5% (Fe 67/15), and 59.7% (Fe 88/37) of la molecules. Fe 75/39
included both Fe 67/15 and Fe 88/37, and Fe 67/15 included Fe 88/37. That these
antisera recognize a common component, different from DRw6 was shown by the
absorption pattern given by antiserum Betz. This antiserum contained anti-DRw6
antibody and others and bound 62.4% of la molecules in the three-step cumulative
binding test. After a two-step absorption with Betz, 42.5% of Ia molecules remained.
Out of these, 28.9, 23 .3, and 27.8% (corresponding to 12.3, 9.9, and 11 .8% as referred
to the initial preparation) were bound . by Fe 75/39, Fe 67/15, and Fe 88/37,
respectively. The only way to accommodate at the same time the proportion of
binding by each antiserum as well as the cross-absorption patterns is shown in Fig. 2,
s The term monospecific has an operational meaning in this context: it refers to the property of an
antiserum to recognize, in the Daudi Ia preparation, a seemingly single determinant, i.e. an antigen which
cannot be dissected further by antisera recognizing a subspecificity (or split). These monospecific antisera
may however contain antibodies against other antigenic determinants, not present in Daudi.
Absorbing antiserum$ Test antiserum Ia binding
Reduction of
la binding§
TH 21.3.75 (25.1%) TH 21 .3.75 12.6 52
TH 19 Varen 75 8.4 68
FD 8013 P 1 16.4 43
TH 19 Varen 75 (19.5%) TH 19 Varen 75 9.3 64
TH 21.3.75 12.1 53
FD 8013 P 1 11 .6 60
FD 8013 P1 (22.9%) FD 8013 P1 8.2 72
TH 21.3.75 13.4 49
TH 19 Varen 75 10.9 58
Normal human serum TH 21 .3.75 26.1
TH 19 Varen 75 26.1
FD 8013 P1 28.91602
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TABLE V
Absorption Patterns by Anti-DC-1 Antisera*
Note that absorption by any ofthe four antisera resulted in almost complete elimination, as compared to
controls, of binding by all the test antisera.
* The experimental procedures are the same as described in Table IV.
$ The percentages of la molecules bound to each antiserum are shown in parentheses. Only one absorption
step was required for the first two antisera to give essentially complete absorption.
§ This was calculated as described in Table IV.
Absorbing antiserum$ Test antiserum la binding Reduction of la binding§
19941/76 (25.6%) 19941/76 0.3 98
Fordice 0 100
CLB 833.2 2.4 85
Corazzala 418 0.8 94
Cerny 7.12.72 0.5 97
Rettler 9.9.70 0 100
Fe 131/4 0.2 99
Fordice (24.3%) Fordice 0.7 96
19941/76 1.6 92
CLB 833.2 1.8 89
Corazzala 418 1.6 88
Cerny 7.12.72 1.0 93
Rettler 9.9.70 0.9 94
Fe 131/4 1.4 91
Fe 77/43 (21.7%) Fe 77/43 5.2 76
19941/76 1.5 92
Fordice 1.2 93
CLB 833.2 1.7 89
Corazzala 418 1.3 90
Cerny 0.9 94
Rettler 9.9.70 1.3 92
Fe 131/6 1.4 92
Fe 96/11 3.9 82
Fe 96/11 (20.5%) Fe 96/11 2.9 86
19941/76 0.5 97
Fordice 0.4 98
CLB 833.2 0.5 97
Corazzala 418 1.1 92
Cerny 7.12.72 0.3 98
Rettler 9.9.70 0.6 96
Fe 131/6 0.2 99
Fe 77/43 5.3 75
Normal human serum 19941/76 18.9
Fordice 17.0
CLB 833.2 15.9
Corazzala 418 13.6
Cerny 7.12.72 14.8
Rettler 9.9.70 15.5
Fe 131/4 15.4
Fe 131/6 17.3
Fe 77/43 22.1
Fe 96/11 21.4TOSI, TANIGAKI, CENTIS, FERRARA, AND PRESSMAN
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TABLE VI
Evidence that DRw6 and DC-1 Determinants are on Different Molecules
Absorption with Anti-DRw6Antisera/Test with Anti-DC-1 Antisera*
Absorption with anti-DC-1 antisera/test with anti-DRw6 antisera*
Note that absorption with antisera belonging to one group does not significantly reduce, in any of the
combinations tested, the binding by antisera belonging to the other group. Most of the time, such
absorption induced an enrichment ofthe molecules carrying the other determinant andthus an apparent
increase of binding as indicated by "+"sign.
* The experimental procedures are the same as described in Table IV.
$ The values in parentheses are the same as those given in Table IV andTable V.
§ This was calculated as described in Table IV.
i.e. assuming a component that we provisionally call DC-2, present on 10-12% of la
molecules. DC-2-positive molecules can be operationally defined as those reacting
with the three antisera 88/37, 75/39, and 67/15, but failing to react with the Betz
antiserum .
Structural Characterization of DRw6 and DC-1 Molecules.
￿
Because molecules carrying
the DRw6 or the DC-1 determinant are bound by monospecific antisera, they could
be separately analyzed for their subunit structure in SDS-polyacrylamide gel electro-
Absorbing antiserum$ Test antiserum Ia binding Variations of la binding§
TH 21 .3.75 (25.1%) Fordice 19.9 +17
Fe 131/4 21 .4 +39
TH 19 Varen 75 !19.5%) Fordice 19.3 +14
Fe 131/4 19.6 +27
FD 8013 P1 (22.9%) Fordice 17.3 +2
Fe 131/4 17.8 +16
Fe 77/43 24.3 +10
Fe 96/11 25.8 +21
Normal human serum Fordice 17.0
Fe 131/4 15.4
Fe 77/43 22.1
Fe 96/11 21 .4
Absorbing antiserum$ Test antiserum Ia binding Variation of la binding§
Fe 77/43 (21 .7%) TH 21.3.75 25.4 -3
FD 8013 P1 35.8 +25
Fe 96/11 (20.5%) TH 21 .3.75 27.5 +5
I'D 8013P1 31.8 +11
19941/76 (25.6%) TH 19 Varen 75 32.7 +25
Fordice (24.3%) TH 19 Varen 75 24.7 -5
Normal human serum TH 21 .3.75 26.1
TH 19 Varen 75 26.1
FD 8013 P1 28.61604
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TABLE VII
Correlation of Antisera Reacting against DC-1 with Defined DR Spectfcities*
DRw7 Ia8
* From the VII Histocompatibility Workshop data for European Caucasoids (3) . Only correlation coeffi-
cient (r) values >0.20 are reported.
$ All the antisera listed are classified as anti-DC-1 antiserum, since their binding with an
1251-labeled Daudi
la preparation was almost completely abolished by absorption with antiserum 19941/76 (7W066), a
representative anti-DC-1 antiserum as shown in the present study.
6
4
2
10
5
(a) Fe 131/4
(Anti-DC-1)
.-32,000 daltons
25,000 da"ons
(b) TH 19 Varen 75
(Anti-DRw6)
(e) CLB 811.1
(AMI-DRw6+DC-I)
0 10 20 30 40
Cathode
￿
Segmsnt number
￿
Anode
FIG. 5.
￿
Analysis by SDS-polyacrylamide gel electrophoresis of Daudi la molecules bound to (a)
Fe 131/4 (anti-DC-1), to (b) TH 19 Varen 75 (anti-DRw6), and to (c) CLB 811 .1 (anti-DRw6 +
DC-1) . 10 id of each antiserum was used. The other experimental conditions are the same as
described in Fig. 1 . Amounts of radioactivity in each immune precipitate were 3,200 cpm for Fe
131/4, 4,100 cpm for TH 19 Varen 75, and 6,100 cpm for CLB 811 .1 . Note that the molecules
bound to anti-DC-1 and to anti-DRw6 give essentially the same pattern in number and position of
the radioactivity peaks. Also note that the radioactivity ratio of the large (32,000 daltons) subunit
over the small (25,000 daltons) subunit is high for DRw6 (bound to TH 19 Varen 75) and low for
DC-1 molecules'(bound to Fe 131/4).
phoresis. Fig. 5 shows representative patterns of the molecules bound by an anti-
DRw6 antiserum (TH 19 Varen 75), an anti-DC-1 antiserum (Fe 131/4), and by a
duo-specific, anti-DRw6 + DC-1 antiserum (CLB 811 .1) . Typical two-subunit struc-
tures, with similar gel migration patterns were found for molecules carrying either
Antiserum$
DRwl DRw2 DRw3
DR
DRw4
r
specificities
DRw5
value
DRw6
7WO06 0.26 - - - - 0.37
7WO07 0.27 - - - - 0.35
7WO10 0.36 - - - - 0.49
7WO66 - 0.44 - - - 0.43
7WO67 - 0.27 - - - 0.33
7W105 - 0.52 - - - 0.39
7W114 - 0.33 - - - 0.29
7W150 - 0.41 - - - 0.46
7W156 - 0.45 - - - 0.38
7W158 - 0.36 - - - 0.39TOSI, TANIGAKI, CENTIS, FERRARA, AND PRESSMAN
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TABLE VIII
Radioactivity Ratio between Large and Small Ia Subunits*
* 125I-labeled Daudi Ia molecules bound by a given antiserum were subjected
to SDS-polyacrylamide gel electrophoresis and radioactivity carried by each
of the large and small subunits was determined. Note that the ratios (L/S)
are high for DRw6 molecules and low for DC-1 molecules. A mixture of
DRw6 and DC-I molecules shows an intermediate value.
determinant. However, when the ratio between the radioactivity counts in the first
large subunit peak and in the second small subunit peak (L/S ratio) was calculated,
a clear difference between DRw6 and DC-1 molecules was found (Table VIII) . DRw6
molecules gave a high L/S ratio, while DC-1 molecules gave a low L/S ratio. As
predicted, molecules bound by antiserum CLB 811 .1 showed an intermediate ratio,
while antisera which bind most Ia molecules showed a ratio somewhat lower than
DRw6 antisera.
Localization of Alloantigenic Specificities at the Subunit Level.
￿
The two noncovalently
linked subunits of which la molecules are formed were separated by treatment with
1 .0% SDS for 30 min at 56°C, followed by SDS-polyacrylamide gel electrophoresis
and elution from the different gel fractions. The peak fractions corresponding to each
of the large and small subunits were then allowed to react against rabbit anti-B-cell
membrane antiserum and various alloantisera. Despite the strong denaturing condi-
tions used, some antisera still bound to the small subunit. As shown in Table IX,
relatively high binding was detected for at least one monospecific anti-DRw6 antise-
rum (TH 19 Varen 75) as well as with an anti-DC-1 antiserum (Fe 77/43) . Compar-
atively high binding were given by more complex antisera, like Betz (DRw6 + x
specificities), Molimer (DRw6 + DC-1 + x specificities) and CLB 811 .1 (DRw6 +
DC-1 specificities). Rabbit anti-B-cell membrane antiserum showed a 47 .3% binding
ofthe small subunit. No antisera gave a significant binding ofthe large subunit except
rabbit anti-B-cell membrane serum which showed a 44.8% binding.
Discussion
The aim of this work has been to link information on B-cell alloantigens derived
from extensive collection of population data based on serological typing with the
information arising from the biochemical analysis of isolated cell membrane compo-
nents.
From the data presented, the following conclusions can be drawn.
Most B Lymphocyte-Specific Antigens of Daudi Cells are on Ia-Like Molecules.
￿
This
Antiserum Specificity L/S ratio Mean
TH 2 .3.75 DRw6 2.65
TH 19 Varen 75 DRw6 2.48 2.45
FD 8013 Pl DRw6 2.21
19941/76 DC- 1 1 .62
Fordice DC- 1 1 .78 1.74
Fe 131/4 DC-1 1 .81
CLB 811 .1 DRw6 + DC-1 2.06
TO-29-01 Broad 2.21
Rabbit anti-B cell Broad 2.111606
￿
IMMUNOLOGICAL DISSECTION OF HUMAN la MOLECULES
TABLE IX
Binding Activity ofIsolated Ia Small Subunits by Alloantisera*
* The large and small subunits of 1251-labeled Ia molecules were separated by SDS-
polyacrylamide gel electrophoresis. Each subunit (about 13,000 cpm) was allowed
to react against 10 At of antiserum overnight at room temperature. Only the data
for the small subunits are shown, since no antiserum tested gave a significant
binding of the large subunit.
$ The values indicate radioactivity (counts/5 min) bound by 10 ILI of serum, after
subtraction of a background value (352 counts/5 min) .
§ The values indicate the percentage of the radioactivity put in reaction (64,698
counts/5 min on the average) . The figures in parentheses are the net percent
binding, i.e. % binding with antiserum - % binding with normal serum.
~~ These were calculated from a one-minute counting.
This value is the mean of triplicate determination (2,197, 2,718, and 2,691 counts/
5 min).
conclusion stems from the facts that a high-positive correlation exists between results
obtained by complement-dependent cytotoxicity assay and those obtained by Ia direct
binding assay with relatively large set of antisera surveyed (Table II), and that
immune complexes from the binding-positive antisera shown in Fig. 2, when analyzed
on SDS-polyacrylamide gel electrophoresis, gave the characteristic pattern of Ia
molecules, i.e. a large (32,000 daltons) and a small (25,000 daltons) subunit (Figs. 1
and 5). It cannot be excluded that a few cytotoxicity reactions may have a different
molecular basis. In fact, at least three cases of cytotoxicity-positive/binding-negative
reactions were found. The reason for this has not been determined yet.
The Ia Binding Reaction Possesses a Sensitivity Comparable to That of the Complement-
Dependent Cytotoxicity Reaction. The difference in sensitivity between the two tests can
be better evaluated on the antisera whose specificity could be well defined, i.e. anti-
DRw6 antisera and anti-DC-1 antisera. All four anti-DRw6 antisera were strongly
and reproducibly cytotoxic and also gave very significant binding reactions. On the
other hand, out of 15 anti-DC-1 antisera detected on the basis of their binding
peculiarities, only eight gave strong cytotoxic reactions, three gave weak and poorly
reproducible reactions, while the other four were completely negative.
Antiserum Specificity
Radioactivity
bound$
Binding§
counts/5 min %
TH 21 .3.75 DRw6 3,574 5.5 (2.2)
TH 19 Varen 75 DRw6 10,332 16.0 (12.6)
FD 8013 P1 DRw6 4,706 7.3 (3.9)
406 DRw6 2,459 3.8 (0.4)
Fordice DC-1 2,370 3.7 (0.3)
19941/76 DC-1 3,507 5.4 (2.1)
Fe 77/43 DC-1 6,542 10.1 (6.7)
CLB 811 .1 DRw6 + DC-1 6,41811 9.9 (6.5)
Molimer DRw6 + DC-1 + x 5,402 8.3 (5.0)
Betz DRw6 + x 15,276 23.6 (20.2)
Fe 75/39 DRw6 + DC-2 + x 3,408 5.3 (1.9)
Fe 67/15 DRw6 + DC-2 + x 4,04811 6.3 (2.9)
Fe 88/37 DRw6 + DC-2 + x 2,205 3.4 (0.0)
Normal - 2,1831 3.4 (0.0)TOSI, TANIGAKI, CENTIS, FERRARA, AND PRESSMAN
￿
1607
The inconsistent cytotoxicity in this group of antisera appears to be not due to the
class or the low avidity of antibodies but mostly due to the low concentration of the
corresponding antigens, i.e. DC-1 molecules, on the surface membrane of Daudi cells
(see below) . Antiserum Molimer is also a remarkable example of a strongly binding
antiserum (77.8% cumulative binding) and yet completely devoid of any cytotoxic
effect on Daudi. This antiserum reacts with DRw6-positive molecules, besides other
components (Fig. 2). In this case, the peculiarity is probably due to the strong
predominance of a noncomplement fixing class of antibodies. Such examples have
already been described (23, 24). It is also possible that this antiserum may possess a
strong anti-complementary activity.
In general, it appears that anti-la alloantisera have a higher affinity than anti-HLA
(A,B,C) antisera (only a minor portion of this latter could be used in binding reactions
[20]). Thus, the performance of Ia typing by radioimmunoassay seems now possible.
Only 30-35% of the Daudi la Molecules Appear to Carry the DRw6 Determinant.
￿
The
determination of the proportion of the Daudi la molecules which carry DRw6
specificity was somewhat laborious, due to the rather poor definition of this antigen
in the VII Workshop, to the lack of monospecific antisera and to their low affinity.
Three anti-DRw6 antisera behaved very similarly in binding and absorption
experiments and the average of the maximum bindings obtained was assumed to
express the proportion of the molecules which carry DRw6 specificity. However, the
percentage of la molecules bound by these antisera only approached a plateau,
without actually reaching it. The mean percentage bound, as obtained by the direct
binding assay under standard conditions (overnight incubation at room temperature)
with the maximum amount of antiserum used (10 I,1), was 27 .0% (26.1, 26.1, 28.9) .
This was increased to 30.2% (27 .0, 29.2, 34.5) by performing three sequential binding
reactions. By increasing the antibody-antigen ratio 10-fold as compared to the
standard conditions, the average percent bound became 37.7% (39.8, 39.0, 34.5).
We feel that a figure of 30-35% for the proportion of the la molecules bound by
anti-DRw6, while perhaps still being an underestimation, cannot be far from the
actual contribution of the DRw6 allele to the Daudi Ia pool. A more definite
determination will require either the availability of monospecific antiserum of a high
affinity or the recognition of an allele to DRw6 expressed in Daudi.
A New B-Cell Alloantigenic Specificity (DC-1) Can Be Defined on Daudi Cells.
￿
This
specificity could be precisely defined by the present immunochemical analysis because
15 different antisera were found to recognize the same subset of Daudi Ia molecules.
It may appear strange that this antigen was not previously defined by serological
analysis at the population level, because it is apparently a frequent specificity of
antisera extensively studied in the VII Histocompatibility Workshop. A possible
explanation lies in the fact that anti-DC-1 antisera usually appear to contain
antibodies against other DR specificities, especially anti-DRwl and DRw2 (see Table
VII) . The definition of DC-1 with the antisera by purely serological means would
have then required extensive cellular absorption experiments. The availability of
purified la preparation instead sorted out this specificity relatively easily. Thus,
immunochemical approach, coupled with serological studies at the population level,
can provide a powerful tool for the genetic analysis of this HLA region.
An additional specificity, DC-2 could be also defined by the immunochemical
analysis, but only with complex, broadly reacting antisera. A search for monospecific1608
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antisera against this component, as well as other antigenic components which may be
present in Daudi cells is in progress.
The DRw6 and the DC-1 Molecules are Probably Controlled by Separate, HLA-Linked
Loci. Two lines of evidence support this conclusion, genetic and biochemical, as
follows : (a) genetic evidence-both DRw6 and DC-1 are controlled by HLA-linked
genes. While there can be little doubt that DRw6 is controlled by the HLA region,
the DC-1 specificity also appears to be HLA-linked because it is in linkage disequilib-
rium with DRw6. In fact, anti-DC-1 antisera studied during the VII Workshop show
a high correlation coefficient (r) with DRw6 in the European caucasoid population
(Table VII) . If DC-1 and DRw6 were alleles, an opposite result, i.e. a negative
correlation would be expected.
Because all antisera shown in Table VII may contain other antibodies, but did not
certainly contain anti-DRw6 antibody, the only possible explanation of this correla-
tion is linkage disequilibrium between DC-1 and DRw6, which in turn implies their
control by two different closely linked loci. The presence of a third, though less well
defined specificity, DC-2, strengthens this two-loci concept.
A possible explanation why a second segregating series has not been evidentiated
by the VII Workshop analysis probably lies in the fact that the products of this second
locus may be in general poorly immunogenic. This would make infrequent the
occurrence of monospecific antisera, because they would be often contaminated by
antibodies against more immunogenic DR antigens. We have previously provided
evidence for a lower immunogenicity of non-DR, B-cell specificities (25). An analogy
can also be drawn with the HLA-C locus, the discovery and analysis of which has
been delayed because of a substantial difference in immunogenicity in respect to the
A and B loci (26) . Since the real proportion of DC-1-positive molecules in Daudi la
is probably lo%,4 a further analogy can be established with C locus products, which
also seems to be represented in lower amount than A and B loci products (27).
(b) Biochemical evidence: DRw6 and DC-1 molecules possess a similar two-subunit
structure (Fig. 5) . This is compatible either with allelism or with the control by closely
linked, homologous loci, coding for the same types of subunits. However, in addition
to the above genetical evidence, the fact that radioactivity ratio between the large
and small subunits is different between DRw6 and DC-1 molecules suggests presence
of differences in the basic structure and favors the linked loci possibility. The difference
in radioactivity ratios is apparently due to a relative difference of iodinationefficiency
of the large and small subunits. It may well correspond to conformational differences
in these two kinds of molecules. It may also reflect a difference in the number of
tyrosine residues in either the large or the small subunit or in both of the subunits. If
we assume that the large subunit is the same in both molecular species, then the data
show that DC-1 molecules can incorporate, under the iodination conditions used, 40%
more iodine into the small subunit than do DRw6 molecules. We have previously
reported a similar finding in iodination of mouse H-2a antigens (H-2Kk and H-2Dd
products) ; the large subunit of H-2Kk molecules contained more radioactivity than
the small subunit, i.e. R2-microglobulin while the reverse was true in case of H-2Dd
molecules (28) .
The two kinds of molecules also exhibited a marked (about five-fold) difference in
papain sensitivity.4 This may recall the differences found among IgG subclasses (29) .
Tanigaki, N., R. Tosi, K. Koyama, and D. Pressman. Purification and separation of subsets of human
la molecules by papain digestion. Manuscript in preparation.TOSI, TANIGAKI, CENTIS, FERRARA, AND PRESSMAN
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An analogy may be seen also with the murine system, where la genes belonging to
different subregions appears to code for molecules which, though sharing a similar
subunit structure, show distinctive structural features (30, 31).
The SmallSubunit Carries Alloantigenic Determinants Controlled by HLA-Linked Loci.
￿
This
conclusion stems from the binding data obtained in isolated subunits. Despite the
extensive denaturation occurring during the isolation procedure and the possible loss
of conformational determinants dependent upon subunit association, about 50% of
both isolated large and small subunits could be bound by a rabbit anti-B-cell
antiserum. Moreover, the small subunit showed a significant level of binding with
some alloantisera (possibly endowed with higher affinity) . At least one monospecific
anti-DRw6 antiserum was among them. These results confirm our data reported
previously (13) . This is direct evidence that the small subunit is coded for by an HLA-
linked gene. This finding agrees with the data of Schwartz et al. (32) showing that the
small subunit carries la alloantigenic determinants in the guinea pig.
On the other hand, no definite conclusion can be drawn on the large subunit. In
spite of its considerable binding activity with rabbit anti-B-cell antiserum, no signif-
icant binding was obtained with the alloantisera tested. This failure to react with
alloantisera may indicate that the large subunit is a nonalloantigenic peptide which
is common to all human Ia molecules,just like the i82-Microglobulin in case of HLA
(A,B,C) antigens. Alternatively, it may simply mean that its alloantigenic determi-
nants are more sensitive to denaturation caused by the isolation procedure. There are
data showing an homology between human Ia large and small subunits by tryptic
peptide analysis (33) . This may or may not be an indication of shared alloantigenic
determinants.
In any case, the two subunits should be controlled by unlinked genes, if the rule for
dimeric proteins composed of different subunits also holds in this case, as it does for
lactic acid dehydrogenase, exoseaminidase A and B, hemoglobin and HLA (A,B,C)
antigens. Our previous observation that the large and small subunits differ xenoan-
tigenically one from another and have essentially no cross-reaction favors the concept
of unlinked gene control (13). In fact, evidence from cellular hybridization studies
indicates that the loci controlling the two subunits are not synthenic (8) .
In conclusion, the following model is proposed: two HLA loci code for homologous,
but distinct forms of the small la subunit . One of these is the DR locus; the second
locus controls the DC-1 specificity in Daudi cells. The two loci are in linkage
disequilibrium and thus they must be very close on the HLA region. The large
subunit is probably controlled by an HLA-unlinked locus. This conclusion needs
confirmation by genetic tests at the family and the population level.
Summary
The immunochemical analysis of Daudi la molecules by a variety of alloantisera
led to the recognition of at least three molecular species carrying different antigenic
determinants: DRw6, DC-1, and DC-2.
Genetic as well as structural evidence indicates that DRw6 and DC-1 molecules are
controlled by separate, HLA-linked loci, rather than by alleles at the same locus. The
alloantigenic determinants appear to be expressed on the small Ia subunit .
DC-1 and DC-2 determinants discussed had not been defined by serological analysis
at the population level, but were demonstrated to be present by immunochemical
analysis at the molecular level.161 0
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